

Res. Asst. OKTAY HALİT AKTEPE

Personal Information

Email: oktay.aktepe@hacettepe.edu.tr

International Researcher IDs

ORCID: 0000-0003-3540-0701

Yoksis Researcher ID: 166297

Education Information

Doctorate, Hacettepe University, Tıp Fakültesi, İç Hastalıkları, Turkey 2012 - Continues

Foreign Languages

English, B2 Upper Intermediate

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Splenic Gaucheroma Leading to Incidental Diagnosis of Gaucher Disease in a 46-Year-Old Man with a Rare GBA Mutation: A Case Report**
Erdal İ., YILDIZ Y., ÖNAL G., AKTEPE O. H., Düzgün S. A., Sağlam A., DÖKMECİ S., SİVRİ H. S.
Endocrine, Metabolic and Immune Disorders - Drug Targets, vol.23, no.2, pp.230-234, 2023 (SCI-Expanded)
- II. **Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wards**
GÜVEN D. C., EROĞLU İ., Ismayilov R., ULUSOYDAN E., AKTEPE O. H., TELLİ DİZMAN G., ARIK Z., DİZDAR Ö., ÜNAL S., METAN G., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.28, no.8, pp.1807-1811, 2022 (SCI-Expanded)
- III. **Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease**
YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., AKSOY S., ERMAN M., KILIÇKAP S., YALÇIN Ş.
JOURNAL OF CLINICAL MEDICINE, vol.11, no.17, 2022 (SCI-Expanded)
- IV. **THSD7A expression: a novel immunohistochemical determinant in predicting overall survival of metastatic renal cell carcinoma treated with targeted therapy**
Aktepe O. H., Gundogdu F., Kosemehmetoglu K., Yeter H. H., Aksoy S., Guven D. C., Sahin T. K., Yuce D., Kertmen N., Dizdar O., et al.
IRISH JOURNAL OF MEDICAL SCIENCE, vol.191, no.4, pp.1561-1567, 2022 (SCI-Expanded)
- V. **The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy**
GÜVEN D. C., ŞAHİN T. K., Erul E., ÇAKIR İ. Y., ÜÇGÜL E., YILDIRIM H. Ç., AKTEPE O. H., ERMAN M., KILIÇKAP S., AKSOY S., et al.
JOURNAL OF CLINICAL MEDICINE, vol.11, no.15, 2022 (SCI-Expanded)
- VI. **The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy**
GÜVEN D. C., KAVGACI G., AKTEPE O. H., YILDIRIM H. H., ŞAHİN T. K., AKSOY S., ERMAN M., KILIÇKAP S., YALÇIN Ş.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.28, no.4, pp.785-793, 2022 (SCI-Expanded)

- VII. **The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study**
GÜVEN D. C., YILDIRIM H. Ç., ERUL E., ŞAHİN T. K., ÇAKIR İ. Y., AKTEPE O. H., KERTMEN N., DİZDAR Ö., AKSOY S.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.52, no.5, pp.1551-1558, 2022 (SCI-Expanded)
- VIII. **A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer**
GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., AKTEPE O. H., DİZDAR Ö., YALÇIN Ş.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.168, 2021 (SCI-Expanded)
- IX. **Correlation Between THSD7A Expression and Tumor Characteristics of Azoxy methane-Induced Colon Cancer Model in Rats**
AKTEPE O. H., ŞAHİN T. K., GÜNER G., GÜVEN D. C., YETER H. H., KURTULAN O., ÖZERCAN İ. H., DİZDAR Ö., YALÇIN Ş.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.32, no.12, pp.1049-1056, 2021 (SCI-Expanded)
- X. **The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy**
AKTEPE O. H., GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇELİKTEKİN B., YETER H. H., YÜCE D., DİZDAR Ö., ERMAN M.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, vol.73, no.10, pp.1957-1963, 2021 (SCI-Expanded)
- XI. **Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality**
GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., İNCESU F. G. G., TAHİLLİOĞLU Y., ÜÇGÜL E., AKSUN M. S., GÜRBÜZ S. Ç., AKTEPE O. H., et al.
BMJ SUPPORTIVE & PALLIATIVE CARE, 2021 (SCI-Expanded)
- XII. **Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors**
GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., ŞAHİN T. K., AKSUN M. S., DİZDAR Ö., AKSOY S., et al.
BIOMARKERS IN MEDICINE, vol.15, no.13, pp.1123-1130, 2021 (SCI-Expanded)
- XIII. **Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy**
GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., CEYLAN F., KERTMEN N., ARIK Z., DİZDAR Ö., et al.
SUPPORTIVE CARE IN CANCER, vol.29, no.9, pp.5417-5423, 2021 (SCI-Expanded)
- XIV. **Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors**
GÜVEN D. C., ŞAHİN T. K., AKSUN M. S., TABAN H., AKTEPE O. H., METİN AKSU N., AKKAŞ M., ERMAN M., KILIÇKAP S., DİZDAR Ö., et al.
SUPPORTIVE CARE IN CANCER, vol.29, no.4, pp.2029-2035, 2021 (SCI-Expanded)
- XV. **Lycopene sensitizes the cervical cancer cells to cisplatin via targeting nuclear factor- κ B (NF- κ B) pathway**
Aktepe O. H., Şahin T. K., Güner G., Arık Z., Yalçın Ş.
Turkish journal of medical sciences, vol.51, pp.368-374, 2021 (SCI-Expanded)
- XVI. **The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma.**
Aktepe O. H., Güner G., Güven D. C., Şahin T. K., Ardiç F. S., Yüce D., Yalçın Ş., Erman M.
Turkish journal of medical sciences, vol.51, pp.757-765, 2021 (SCI-Expanded)
- XVII. **Survival Outcomes of Patients in Advanced Non-Clear Renal Cell Carcinoma Treated with Pazopanib: A Retrospective Single Institution Experience**
AKTEPE O. H., ERMAN M.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.31, no.3, pp.170-177, 2021 (SCI-Expanded)
- XVIII. **Defining the Optimal Regimen for Stage III Colon Cancer: Concerns with Study Design**
GÜVEN D. C., GÜNER G., AKTAŞ B. Y., AKTEPE O. H., TABAN H., ARIK Z.
CLINICAL COLORECTAL CANCER, vol.19, no.3, 2020 (SCI-Expanded)

- XIX. **Anti-prostate cancer activity of a nanoformulation of the spleen tyrosine kinase (SYK) inhibitor C61**
ŞAHİN T. K., AKTEPE O. H., UCKUN F. M., YALÇIN Ş.
ANTI-CANCER DRUGS, vol.31, no.6, pp.609-616, 2020 (SCI-Expanded)
- XX. **Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group Study**
YILDIZ B., KUCUKARDA A., GOKYER A., DEMIRAY A. G., PAYDAŞ S., ARAL I. P., GÜMÜŞAY Ö., BİLİCİ A., AKDENİZ N., BAHCECİ A., et al.
JOURNAL OF BUON, vol.25, no.2, pp.1130-1135, 2020 (SCI-Expanded)
- XXI. **Complete responses to two different anti-PD1 agents in a metastatic melanoma patient**
KILIÇKAP S., GÜVEN D. C., AKTEPE O. H., AKTAŞ B. Y., DİZDAR Ö.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.2, pp.496-499, 2020 (SCI-Expanded)

Articles Published in Other Journals

- I. **Prognosis of Liposarcoma Patients in Modern ERA: Single-Center Experience**
DEMİR M., GÜVEN D., AKTAŞ B. Y., GÜNER G., AKTEPE O. H., TABAN H., KARAKAS Y., KILIÇKAP S., KARS A., TURKER A., et al.
SOUTH ASIAN JOURNAL OF CANCER, vol.11, pp.287-292, 2022 (ESCI)
- II. **Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma**
ISMAİYLOV R., AKTEPE O. H., SARDAROVA K., LEBLEBİCİ C. B., ERMAN M.
EURASIAN JOURNAL OF MEDICINE, vol.54, no.1, pp.77-79, 2022 (ESCI)
- III. **Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy**
YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., AKTAŞ B. Y., GÜNER G., DİZDAR Ö., AKSOY S., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, vol.6, no.1, pp.59-63, 2022 (ESCI)
- IV. **Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma**
AKTEPE O. H., GÜNER G., GÜVEN D. C., TABAN H., YILDIRIM H. Ç., ŞAHİN T. K., ARDİC F. S., YETER H. H., YÜCE D., ERMAN M.
TURKISH JOURNAL OF UROLOGY, vol.47, no.2, pp.113-119, 2021 (ESCI)
- V. **Sequential vitamin D and parathyroid hormone measurement in patients with septic shock: Could they be prognostic marker in septic shock**
YETER H. H., AKTEPE O. H., TOPELİ İSKİT A.
Experimental Biomedical Research, vol.1, no.3, pp.90-102, 2018 (Peer-Reviewed Journal)
- VI. **Urinary Tract Infection Caused by Raoutella Ornithinolytica in a Patient With Bladder Cancer**
YETER H. H., AKTEPE O. H.
Türkiye Klinikleri Journal of Medical Research, vol.24, no.3, pp.216-218, 2016 (Peer-Reviewed Journal)

Refereed Congress / Symposium Publications in Proceedings

- I. **Is obesity paradox real or not? The role of leptin in septic shock patients**
AKTEPE O. H., KARA A., YETER H. H., TOPELİ İSKİT A.
European society of intensive medicine (ESICM 2016), 1 - 05 October 2016, vol.4
- II. **Akut Böbrek Hasarı Gelişim Zamanının Kritik Hastalarda Mortalite Üzerine Etkisi: Yoğun bakımda kazanılmış akut böbrek hasarı yeni bir terminoloji mi?**
YETER H. H., KARA A., EYÜPOĞLU N. D., ÇELEBİ F., AKTEPE O. H., AKÇAY Ö. F., PASAYEV T., YILDIRIM T., ARICI M., TOPELİ İSKİT A.
18. ULUSAL HİPERTANSİYON VE BÖBREK HASTALIKLARI KONGRESİ, Girne, Cyprus (Kktc), 12 - 15 May 2016

Metrics

Publication: 35

Citation (WoS): 4

Citation (Scopus): 82

H-Index (WoS): 1

H-Index (Scopus): 4

Non Academic Experience

SAĞLIK BAKANLIĞI-Dr. Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi

SAĞLIK BAKANLIĞI-Sorgun Devlet Hastanesi